Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2019-02-14
Target enrollment:
Participant gender:
Summary
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora
B）、VEGFR/PDGFR/c-Kit、CSF-1R targets.
This clinical trial is studying the efficacy and safety of chiauranib works in treating
patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the
latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical
benefit.